Lingmin Zhang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Book of Award

Prof. Lingmin Zhang | Pharmacology, Toxicology and Pharmaceutical Science | Research Excellence Award

Guangzhou Medical University | China

Prof. Lingmin Zhang is a leading researcher whose work integrates pharmaceutics, biomedical materials, and gene delivery, contributing significantly to advanced therapeutic strategies, particularly in lung cancer and inflammatory diseases. With 3,077 citations , 79 publications, and an h-index of 27, the researcher's scholarly impact is widely recognized. The work focuses on innovative nano-based and biomimetic delivery platforms, including nano-PROTACs, exosomes, microfluidic nanovesicles, and CRISPR/Cas9 carriers, offering transformative possibilities for targeted and precision medicine. Supported by major grants from the National Natural Science Foundation of China (projects 82572415, 82072047, 81700382), the researcher has developed cutting-edge strategies such as reprogramming tumor-associated macrophages, overcoming drug resistance in lung cancer, and reversing epigenetic silencing through nanoparticle-mediated gene delivery. Influential publications in high-impact journals—including Journal of Controlled Release, Drug Resistance Updates, ACS Nano, Angewandte Chemie, Advanced Science, and Molecular Cancer—highlight breakthroughs in nano-therapeutics, PROTAC technologies, artificial exosomes, and nucleic-acid delivery systems. Collectively, these contributions position the researcher at the forefront of translational nanomedicine, with ongoing work offering new directions for precision oncology, regenerative strategies, and next-generation drug delivery platforms.

Profile : Scopus | Orcid

Featured Publication

He, M., Peng, Q., Yang, Q., Guan, X., Liu, Q., Chen, R., Zhou, D., Wang, L., Zhang, Y., Li, S., Su, J., & Zhang, L. (2026). In situ reprogramming of tumor associated macrophages with versatile nano-epigenetic inhibitor for lung cancer therapy. Journal of Controlled Release, 2026, 114497.

Zhang, L., He, L., Lin, Y., Wei, J., Tang, S., Lei, X., Lin, X., Zhou, D., Fu, L., Li, Y., He, J., Liang, L., & Yu, X. (2026). The novel strategy to overcome drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells. Drug Resistance Updates, 84, 101316.

Chen, S., Chen, E., Su, J., Gong, Y., Tang, S., Qin, A., Shen, A., Tang, S., & Zhang, L. (2025). Magnetically navigated nano-PROTAC ameliorates acute lung injury. Journal of Nanobiotechnology, 23, 622.

Li, X., Qin, Z., Wang, S., Zhang, L., & Jiang, X. (2025). Microfluidics-assembled nanovesicles for nucleic acid delivery. Accounts of Chemical Research, 58, 570–582.

Liang, L., Peng, W., Qin, A., Zhang, J., Chen, R., Zhou, D., Zhang, X., Zhou, N., Yu, X., & Zhang, L. (2024). Intracellularly synthesized artificial exosome treats acute lung injury. ACS Nano, 18(32), 21009–21023.

Guan, X., Xu, X., Tao, Y., Deng, X., He, L., Lin, Z., Chang, J., Huang, J., Zhou, D., Yu, X., Wei, M., & Zhang, L. (2024). Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy. Journal of Nanobiotechnology, 22, 692.

Zhang, L., Lin, Y., Li, S., Guan, X., & Jiang, X. (2023). In situ reprogramming of tumor-associated macrophages with internally and externally engineered exosomes. Angewandte Chemie International Edition, 62(11), e202217089.

Liang, L., Cen, H., Huang, J., Qin, A., Xu, W., Wang, S., Chen, Z., Tan, L., Zhang, Q., Yu, X., Yang, X., & Zhang, L. (2022). The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy. Molecular Cancer, 21(1), 186.

Zhang, H., Peng, R., Chen, S., Shen, A., Zhao, L., Tang, W., Wang, X., Li, Z., Zha, Z., Yi, M., & Zhang, L. (2022). Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy. Advanced Science, 9(29), 2202039.

Zhang, L., Wang, L., Xie, Y., Wang, P., Deng, S., Qin, A., Zhang, J., Yu, X., Zheng, W., & Jiang, X. (2019). Triple-targeting delivery of CRISPR/Cas9 to reduce the risk of cardiovascular diseases. Angewandte Chemie International Edition, 58(36), 12404–12408.

Sophie Grigolo | Immunology and Microbiology | Young Researcher Award

Published on by Book of Award

Mrs. Sophie Grigolo | Immunology and Microbiology | Young Researcher Award

University of Fribourg | Switzerland

Mrs. Sophie Grigolo is an emerging researcher specializing in cellular and molecular biology, with a strong focus on cancer research, particularly clear-cell renal-cell carcinoma (ccRCC). Her work encompasses extensive laboratory expertise in cell culture using human kidney cancer cell lines (A-498, ACHN, Caki-1, and Caki-2) and a range of analytical assays including BrdU Cell Proliferation, MTT, LDH, and Live-or-Dye™ Fixable Viability Staining. She is proficient in advanced molecular biology techniques such as polymerase chain reaction (PCR), agarose gel electrophoresis, western blotting, genotyping, flow cytometry, and immunohistochemistry (IHC), which she applies to elucidate cancer cell behavior and therapeutic responses. Her publications, including studies on immunotherapy in ccRCC and the role of IL-2 receptor expression in renal carcinoma cells, contribute to advancing understanding of tumor immunology and targeted therapies. Sophie has also shared her findings at prestigious scientific forums, including the International Student Congress of (bio)Medical Sciences and the Annual European Student Symposium on Anatomical Research, where her work has earned recognition for excellence. Through her research and technical acumen, she continues to contribute to the evolving field of cancer biology and the development of innovative therapeutic approaches.

Profile : Orcid

Featured Publications

Grigolo, S., Fellay, I., & Filgueira, L. (2025). IL-2 receptor expression in renal cell carcinoma cells: IL-2 influences cell survival and induces cell death. Current Issues in Molecular Biology, 47(10), 830.

Grigolo, S., & Filgueira, L. (2024). Immunotherapy of clear-cell renal-cell carcinoma. Cancers, 16, 2092.

Shahbaz Khan | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Published on by Book of Award

Dr. Shahbaz Khan | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Pharmacy Academy, Institute of Foreign Trade and Management University | India

Author Profile

Scopus

Orcid

Google Scholar

Early Academic Pursuits

Dr. Shahbaz Khan’s academic journey reflects a strong commitment to pharmaceutical sciences, beginning with foundational studies in pharmacy and advancing through specialized postgraduate training in pharmacology. His scholarly dedication culminated in a doctoral degree in pharmaceutical sciences, where his research explored the phytochemical and pharmacological activities of Betula alnoides bark extracts. These early academic achievements not only provided him with a robust understanding of pharmacological principles but also shaped his future research interests in neuropharmacology, neuroscience, and inflammation studies.

Professional Endeavors

Dr. Khan’s professional career spans diverse academic and administrative roles in reputed institutions. He has served as a faculty member in both assistant and associate professor capacities, mentoring students at undergraduate, postgraduate, and doctoral levels. Alongside his teaching and research responsibilities, he has contributed significantly to institutional development through administrative positions such as hostel warden. His teaching philosophy combines rigorous academic training with practical exposure, ensuring that his students are well-prepared for the pharmaceutical and healthcare industries.

Contributions and Research Focus

Dr. Khan’s research portfolio is extensive and multidisciplinary, with particular emphasis on neuropharmacology, phytochemistry, and inflammation-related pathologies. His studies delve into the therapeutic potential of medicinal plants, the development of advanced drug delivery systems, and the role of nutraceuticals in managing neurodegenerative and chronic diseases. His work also encompasses nanomedicine, regenerative medicine, and targeted therapies, leading to innovations in formulations and biomedical applications. By integrating modern pharmacological techniques with traditional medicinal knowledge, he has made meaningful contributions to both preclinical research and applied therapeutic strategies.

Accolades and Recognition

Dr. Khan has earned multiple national and international honors that recognize his academic excellence and research contributions. His achievements include prestigious travel grants for participating in global scientific programs organized by international brain research organizations, as well as awards for specialized training in molecular neuropharmacology. These recognitions underscore his role as a scholar of global repute and his ability to represent Indian pharmaceutical research on international platforms.

Impact and Influence

The impact of Dr. Khan’s work extends beyond his own research, influencing students, collaborators, and the broader scientific community. His publications in high-impact journals have contributed to advancing knowledge in pharmacology, medicinal chemistry, and biomedical sciences. His patents and innovations in pharmaceutical formulations highlight his ability to bridge the gap between laboratory research and practical healthcare solutions. Through book authorship and editorial contributions, he has also enriched the academic resources available to scholars worldwide.

Legacy and Future Contributions

Dr. Khan’s legacy lies in his ability to combine teaching, research, and innovation into a cohesive professional identity. His mentorship has guided many students toward successful careers in pharmacy and research. Looking ahead, he aims to expand his research in neurotherapeutics, nanomedicine, and herbal pharmacology, with a focus on developing novel, safe, and effective treatments for neurological and inflammatory disorders. His future contributions are expected to further strengthen the role of pharmaceutical sciences in addressing global health challenges.

Publications

Exploring Betula alnoides Bark: Insilico and Preclinical Insights into its Antioxidant and Lipid-Lowering Effects in Hypercholesterolemia
Authors: Shahbaz Khan, Alka Lohani, Prashant Tiwari, Sunil Kumar Kadiri
Journal: Obesity Medicine
Year: 2025

Innovative nanomedicine for fungal infections: Advancing treatments through nanotechnology and mycological approaches
Authors: Alka Lohani, Ritika Saxena, Shahbaz Khan, Ana Figueiras, Filipa Mascarenhas-Melo
Journal: Journal of Drug Delivery Science and Technology
Year: 2025

Tailored polymeric hydrogels for regenerative medicine and drug delivery: From material design to clinical applications
Authors: Alka Lohani, Ritika Saxena, Joana Galvão Duarte, Shahbaz Khan, Ana Figueiras, Filipa Mascarenhas-Melo
Journal: International Journal of Pharmaceutics
Year: 2025

pH-responsive IPN beads of carboxymethyl konjac glucomannan and sodium carboxymethyl cellulose as a controlled release carrier for ibuprofen
Authors: Alka Lohani, Ritika Saxena, Shahbaz Khan, Filipa Mascarenhas-Melo
Journal: International Journal of Biological Macromolecules
Year: 2024

An Insight Into Neuropathic Pain: A Systemic and Up-To-Date Review
Authors: Himanshu Sharma, Tanzeeb Rani, Shahbaz Khan
Journal: International Journal of Pharmaceutical Sciences and Research
Year: 2023

Conclusion

Through unwavering dedication to research, teaching, and innovation, Dr. Shahbaz Khan has established himself as a respected authority in pharmaceutical sciences. His contributions continue to inspire students, peers, and the scientific community at large, ensuring his place as a pivotal contributor to advancements in healthcare and pharmacology.